Mr. Caffo has been Candel’s Chief Business Officer since September 2020. He was most recently CBO at ALX Oncology, an immuno-oncology company where he played a central role in the company’s financing including the series B and C and debt financings totaling $120 million, as well as the company’s $186M IPO. He was also responsible for all strategic partnering activities. Prior to ALX Oncology, he was previously President and CEO of Presage Biosciences, an oncology company that developed the first intratumoral microdosing platform for evaluation of multiple oncology agents. While at Presage he led the company’s partnering strategy, resulting in over $30 million in upfront cash. Mr. Caffo’s 26-year industry career has been focused on cancer therapeutics, personalized medicine, and applications of genomic technology. Mr. Caffo also led drug in-licensing at Perlegen Sciences, a genomic medicine spin-off of Affymetrix. Prior to that, he worked at Applied Biosystems (now Life Technologies) and its sister company Celera (now Quest Diagnostics) for 11 years in a number of technical and business roles, including managing the company’s genomics service business. Mr. Caffo has a B.S. in Microbiology from Pennsylvania State University.